Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362884 | 1.00 | ALDH1A1 (0.55) | ALDH1A1NPC1SMN1; SMN2RAB9APTPN1 | |
| SCHEMBL11830878 | 0.85 | PTPN1 (0.59) | ALDH1A1NPC1SMN1; SMN2RAB9APTPN1 | |
| SCHEMBL2644205 | 0.85 | ALDH1A1 (0.58) | ALDH1A1NPC1SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL30420736 | 0.84 | SMN1; SMN2 (0.58) | ALDH1A1NPC1SMN1; SMN2RAB9APTPN1 | |
| SCHEMBL7835274 | 0.84 | SMN1; SMN2 (0.58) | ALDH1A1NPC1SMN1; SMN2RAB9APTPN1 | |
| SCHEMBL3379510 | 0.82 | HDAC1 (0.60) | ALDH1A1NPC1SMN1; SMN2RAB9APTPN1 | |
| SCHEMBL12600053 | 0.81 | HDAC3 (0.48) | ALDH1A1NPC1SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL12600064 | 0.81 | KMT2A (0.45) | ALDH1A1SMN1; SMN2RAB9AKDM4EKMT2A | |
| SCHEMBL1974978 | 0.81 | PTPN1 (0.71) | ALDH1A1NPC1SMN1; SMN2RAB9APTPN1 | |
| SCHEMBL29489791 | 0.81 | PTPN1 (0.71) | ALDH1A1NPC1SMN1; SMN2RAB9APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113980001-B | Pyrazolol-pyridazinone coupling compound, pharmaceutical composition thereof and application of pyrazolol-pyridazinone coupling compound in medicines | 贵州医科大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-108558833-B | Pyrazole alcohol compound, pharmaceutical composition thereof and application thereof in medicines | 贵州医科大学 | 2022-03-04 | — | — | CN | disclosed |
| CN-113980001-A | Pyrazole alcohol-pyridazinone coupling compound, pharmaceutical composition thereof and application thereof in medicines | 贵州医科大学 | 2022-01-28 | — | — | CN | disclosed |
| CN-112209907-A | Method for synthesizing dihydrofuran containing 1, 3-indene dione spiro-skeleton by using microchannel reaction device | 南京先进生物材料与过程装备研究院有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20140018384-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | PRONOXIS AB (SE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018384-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | PRONOXIS AB (SE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018384-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | PRONOXIS AB (SE) | 2014-01-16 | — | — | US | disclosed |
| WO-2012127214-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | PRONOXIS AB (SE) | 2012-09-27 | — | — | WO | disclosed |
| WO-2012127214-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | PRONOXIS AB (SE) | 2012-09-27 | — | — | WO | disclosed |
| EP-1425010-B8 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | JANSSEN PHARMACEUTICALS INC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-6063800-A | Modulators of molecules with phosphotyrosine recognition units | NOVO NORDISK A/S (DK) | 2000-05-16 | — | — | US | disclosed |
| US-5972978-A | FOR USE IN TREATMENT OF HUMAN AND ANIMAL DISORDERS, USE FOR PURIFICATION OF PROTEINS OR GLYCOPROTEINS, USE IN DIAGNOSIS | NOVO NORDISK A/S (DK) | 1999-10-26 | — | — | US | disclosed |
| US-5958957-A | PROTEIN TYROSINE PHOSPHATASES, PROTEINS WITH SRC-MONOLOGY 2-DOMAINS; ANTICARCINOGENIC,-TUMOR AND DIABETIC AGENTS; PURIFICATION OF PROTEINS AND GLYCOPROTEINS; MEDICAL DIAGNOSIS | NOVO NORDISK A/S (DK) | 1999-09-28 | — | — | US | disclosed |
| WO-1997040017-A2 | MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
| US-RE30739-E | ANTIDEPRESSANT | BEECHAM GROUP LIMITED (GB) | 1981-09-08 | — | — | US | disclosed |
| US-4167515-A | Anorexic chromans | BEECHAM GROUP LIMITED (GB) | 1979-09-11 | — | — | US | disclosed |
| US-4153617-A | Anorexic chromans | BEECHAM GROUP LIMITED (GB) | 1979-05-08 | — | — | US | disclosed |
| US-4148909-A | Chromans to treat depression and reduce appetite | BEECHAM GROUP LIMITED (GB) | 1979-04-10 | — | — | US | disclosed |
| US-4146539-A | MOOD MODIFYERS, ANTIDEPRESSANTS | BEECHAM GROUP LIMITED (GB) | 1979-03-27 | — | — | US | disclosed |
| US-4080335-A | Anorexic chromans | BEECHAM GROUP LIMITED (GB) | 1978-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018384-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | NOX4, NOX1, CYBB | ALDH1A1 517/4885NPC1 3998/4885SMN1; SMN2 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.